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journal homepage: www.elsevier .com/locate /nmcdLETTER TO THE EDITORNo association between the degree of liver steatosis
and early signs of vasculopathy in T2DMNon alcoholic fatty liver disease (NAFLD) is both an inde-
pendent and an associated risk factor for cardiovascular
(CV) disease in the general population [1]. Whereas the
association between NAFLD, and early signs of vasculop-
athy, such as an increased intima-media thickness (IMT) and
a decreased flow-mediated vasodilation (FMD), has been
reported in the general population, such an association in
type 2 diabetes mellitus (T2DM) is controversial. In T2DM
patients with NAFLD FMD was decreased [2], whereas IMT
was not different, with respect to patients without liver
steatosis [3]. Should a (causative) relationship between
hepatic steatosis and early signs of vasculopathy exists, the
degree of liver fat should be associated with a worse
endothelial function and morphology. However, despite the
bulk of data generated on this complex association, insuf-
ficient reports exist on T2DM.
To this aim, we measured the extent of liver fat, average
IMT, the presence and type of carotid plaques, and FMD, in
sixty consecutive T2DM patients largely affected by
features of the MS. Liver steatosis, IMT, and presence and
types of carotid plaques, were evaluated by ultrasonog-
raphy (using an HDI 5000 Philips Medical Systems apparatus,
Bothell, WA, USA), with a broad-band width phased array
transducer (2e5 MHz). Steatosis was divided into four
classes following the traditional US classification (class 0:
absence; classes 1e3: increasing degrees, of steatosis) [4].
IMT was assessed using standard procedures [5]. FMD was
evaluated in 45 patients using an internationally validated
approach [6]. Only six patients were current smokers, and
seven had a positive history for CV disease (five for ischemic
heart disease, and two for cerebrovascular disease). No
subject was positive for hepatitis C virus infection.
The overall prevalence of steatosis was 88% (34% mild,
34% moderate e 20% severe). Average IMT was
0.88  0.03 mm (Mean  SE), significantly greater
(p < 0.0001) than the mean value of a healthy, age- and sex
matched population at our Institution (0.72  0.03 mm).
Fifty-eight percent of patients had carotid plaques.
Average FMD in the patients (5.02  0.81%) was lower
(p < 0.001) than the normal values of healthy, age- and sex
matched individuals from our Institution (6.56  0.60%).0939-4753/$ - see front matter ª 2011 Elsevier B.V. All rights reserved
doi:10.1016/j.numecd.2011.11.008Nevertheless, there was no difference, among the four
classes of steatosis, in either FMD (class 0: 5.10  0.89%;
class 1: 4.97  0.46%; class 2: 4.73  0.40%; class 3:
5.25  0.17%) (p Z 0.543 by ANOVA), average IMT
(0.82  0.08; 0.93  0.05; 0.85  0.05; and 0.85  0.06 mm,
respectively; p Z 0.760 by ANOVA), or the prevalence of
carotid plaques (43; 70; 60 and 69% respectively,
p Z 0.644).
In conclusion, in T2DM patients largely exhibiting
features of the MS, the degree of liver steatosis is not
associated with early signs of (sub)clinical atherosclerosis
and altered vascular function. These data question the role
of liver fat as a direct determinant of early signs of vascul-
opathy in T2DM. Alternatively, it is possible that the burden
of cardiovascular risk factors already present in these T2DM
patients, obscure the possible contribution given by the
degree of steatosis, on early signs of arteriosclerosis.References
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